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BRCA1/2 carriers, even if they do not belong to the BRCA1/2 phenotype.
Case presentation
A 54-year old BRCA2-associated breast cancer patient complained of
abnormal vaginal bleeding, while on theﬁfth year of adjuvant treatment
with tamoxifen. Five years previously, she had been diagnosed with es-
trogen and progesterone receptor positive breast cancer (T2N0M0),
treated with modiﬁed radical mastectomy, anthracycline-based adju-Introduction
Hypersensitivity to DNA-damaging agents is characteristic of BRCA1/
2-deﬁcient ovarian cancer. BRCA1/2 carriers have an impaired ability to
repair double-stranded DNA breaks through homologous recombination
(Konstantinopoulos et al., 2010). When treating ovarian cancer in these
patients, the platinum–DNA adducts are not easily excised due to the
loss of homologous recombination. Although the increased survival in
BRCA1/2-associated ovarian cancer patients is caused bymultiple factors,
heightened DNA-damaging drug sensitivity is clearly observed when
human cancer cells have mutated or epigenetically silenced BRCA1/2
(Konstantinopoulos et al., 2010).
In this report, we describe the case of a BRCA2 patient with an unex-
pected long survival after treatment for distant metastasis of uterine
carcinosarcoma. Carcinosarcoma does not belong to the BRCA1/2 phe-
notype and, in this case, previous tamoxifen treatment was considered
the cause of this very aggressive endometrial cancer. The unexpected
survival of the patient (over 5 years since treatment of metastatic dis-
ease without any other evidence of disease) raises the possibility that
sensitivity to platinum and other DNA-damaging agents may be aCancer Risk Evaluation Clinic,
ima Basto, 1099-023 Lisboa,
).
-ND license.vant chemotherapy and tamoxifen (20 mg qid).
Although a suspicious endometrial lesion was observed by
endovaginal ultrasound and CT scan, no malignant tumor cells were
observed on endometrial biopsy. Total hysterectomy and bilateral
adnexectomy were performed. At surgery, the endometrial cavity was
found to be totally occupied by a solid polypoid tumor with 12 cm in
its largest dimension. Post-operative histology showed a carcinosarco-
ma with heterologous mesenchymal elements. There was no invasion
of themyometrium, the isthmus or the uterine cervix (Fig. 1). Adjuvant
treatment consisted of external radiotherapy and brachytherapy.
Ninemonths later, an abdominal CT scan disclosed a retroperitoneal
tumor, which was surrounding the cephalic portion of the pancreas
(8.1×5.6 cm) and the inferior vena cava (Fig. 2). During laparotomy,
the lesion was not amenable for resection, but surgical biopsy con-
ﬁrmed lymph node metastasis of the sarcomatous fraction of uterine
carcinosarcoma (Fig. 3).
Chemotherapy with cisplatinum (80 mg/m2) and ifosfamide
(4500 mg/m2) per cycle, every 3 weeks, was started. Partial response
was observed by abdominal CT scan but no abnormally high uptake
was reported on PET scan. Subsequent surgery allowed for the complete
removal of the residual tumor. Only ﬁbrosis and necrotic tissue were
observed on histopathological analysis, without viable sarcomatous or
other neoplastic cells. Without any further treatment, the patient is
alive with no evidence of disease, 65 months after the surgery of the
relapse.
Discussion
Carcinosarcomas are rare, aggressive neoplasms of the female genital
system. Three percent of uterine tumors have this histology, composed
Fig. 1. Carcinosarcoma: both the adenocarcinomatous (thick arrow) and the
chondrosarcomatous (thin arrow) components are present (H&E, original magni-
ﬁcation ×100).
Fig. 3. In the retroperitoneal mass excised 9 months after primary diagnosis, only the
undifferentiatedmesenchymal component was present (H&E, original magniﬁcation ×200).
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survivors, previous treatment with tamoxifen increases the risk for
endometrial cancers and also for carcinosarcomas (Curtis et al., 2004).
Tamoxifen is also considered the main contributor for the cases of endo-
metrial cancers observed in BRCA1/2 patients (Beiner et al., 2007).
Long-term survival following the diagnosis of uterine carcinosar-
coma is rare, with an estimated ﬁve year overall survival rates of 33
to 39% (Gonzalez Bosquet et al., 2010). Most patients suffer disease
recurrence, and survival after distant relapse is usually less than
4 months (Gonzalez Bosquet et al., 2010). As observed in our patient,
recurrence occurs mostly within 12 months of treatment, and che-
motherapy is usually the treatment of choice (Gonzalez Bosquet etFig. 2. Retroperitoneal tumor disclosed by abdominal CT scan (arrow).al., 2010). Combination regimens with cisplatinum and doxorubicin
or ifosfamide were found to be the most effective, but with greater
toxicity than monotherapy. More recently, better tolerated regimens
of platinum/taxane associations are being increasingly used in the
treatment of carcinosarcoma (Curtin et al., 2001).
Our case is remarkable because an early relapsing uterine carcinosar-
coma, mainly composed of sarcomatous components, which are usually
associated with poor outcome (Fujii et al., 2000), was extremely sensi-
tive to cisplatinum and ifosfamide. The patient is alive, with no evidence
of disease, more than ﬁve years after starting chemotherapy treatment
that led to a complete pathological response. When reviewing the litera-
ture, only three reports for a total of four long term survivors of uterine
carcinosarcoma are found. Ko et al. (2005) report a BRCA1 patient with
a peritoneal carcinosarcoma treated with cisplatinum, ifosfamide and
pelvic radiotherapy, with no recurrence of disease after 5 years. This pa-
tient is comparable to ours in several ways: both are BRCA1/2mutation
carriers, both had extensive metastatic disease and, in both cases, plati-
num based chemotherapy led to a long overall survival. The other report
published in the literature describes two patients with pelvic relapses
(one of them also with supraclavicular node involvement) (Dass et al.,
1993), and another one reports on one patient alive, after ﬁve years of
chemotherapy treatment for pulmonary metastasis from uterine
carcinosarcoma (Shamseddine et al., 2003). There is no information
concerning the BRCA1 or BRCA2 carrier status of these patients.
We suggest that the long term survival of our BRCA2 patient and of
the BRCA1 patient described by Ko et al. (2005) may be related to
their BRCA1/2 germinal status. This is not to imply any causative relation
between the diagnosis of carcinosarcoma and the BRCA1/2 mutations,
since tamoxifen is clearly the most probable cause of the disease in
the case we report. However, the complete pathological response to
cisplatinum and ifosfamide of a serious distant relapse, and particularly,
the duration of this response, are all difﬁcult to explain without the
unique sensitivity to DNA-damaging drugs observed in BRCA1/2 pa-
tients. Platinum-drug sensitivity observed in BRCA1/2-deﬁcient cancers
is explained because it provokes DNA double strand breaks. BRCA1/
2-deﬁcient individuals have a germinal defect in the repair of these
breaks, potentiating platinum activity. Ifosfamide, as a bifunctional
alkylating agent, is able to form crosslinks with DNA, resulting in inhibi-
tion of DNA synthesis and function. It is possible that a synergistic effect
between cisplatinum and ifosfamide may have contributed to the
46 A. Clara et al. / Gynecologic Oncology Reports 4 (2013) 44–46unexpected long-term response in our patient. Independent of the
BRCA1/2-associated phenotypes, increased sensitivity to these drugs
seems to be a general feature of BRCA1/2mutation carriers.
The sarcomatous fraction of carcinosarcoma is observed either in
the presence of both components (carcinoma and sarcoma) or
alone (after the evolution of a heterologous cancer into a tumor ex-
clusively composed by sarcomatous elements). These cancers are
monoclonal and even the sarcomatous fraction has epithelial origin.
Due to the phylogenetic evolution that leads to tumor heterogene-
ity, response to chemotherapy may be mediated by common muta-
tions located in the trunk of the phylogenetic tree (Gerlinger et al.,
2012).
In conclusion, we suggest that three factors explain the long survival
of our patient: her BRCA2 status thatmakes all her cells defective in DNA
repair, the unique activity of DNA-damaging drugs in BRCA1/2mutation
carriers, and the sensitivity of the sarcomatous relapse to cisplatinum
and ifosfamide. Sensitivity to platinumand other DNA-damaging agents
may be a general feature of cancers in BRCA1/2 patients, even for neo-
plasms not belonging to the expected BRCA phenotype.Conﬂict of interest statement
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